Patent · US Active

Highly concentrated formulations of soluble Fc receptors

US11266708B2 · kind B2 · utility

0Cited by

4References

10Claims

0Family size

Assignee

SUPPREMOL GMBH · DE

Inventors

Peter Sondermann · Stockdorf, DE
Thomas Pohl · Holzgerlingen, DE

Key dates

Filing date	Jan 4, 2019
Grant date	Mar 8, 2022
Priority date	—
Expiry date	Jan 4, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P37/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble FcγRIIB receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.